• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 20th December 2018

Making the Most of Health Data to Deliver Pharmaceutical Innovation: What Are the Legal Barriers?

OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation. As a society, we place a huge value on data: from supermarkets using our previous shopping habits to help us effortlessly…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.

As a society, we place a huge value on data: from supermarkets using our previous shopping habits to help us effortlessly select our preferred tea bags, to insurance companies tailoring their offerings to our specific motoring needs. With the proliferation of digital technology, we are collecting more and more data in real-time, through which we can discern patterns in behaviour and begin to predict events. The health care market is no exception. 

Despite the exciting new opportunities that the expansion of health data creates, these opportunities are necessarily bounded by the legal framework which governs how data can be collected, accessed, and used. In an OHE Consulting Report, recently published, we outline the main legal barriers to the better use of health data to deliver pharmaceutical innovation. To identify tangible and specific legal barriers, we investigated the legal issues arising from six key activities along the pharmaceutical lifecycle:

  1. Epidemiology and pharmacoepidemiology: identifying unmet need
  2. Pharmacogenetics: targeting development
  3. Interventional studies
  4. Non-interventional studies
  5. Pharmacovigilance
  6. Managed entry agreements

A key development in this space was the introduction of the General Data Protection Regulation (GDPR) earlier this year. For most, mention of the GDPR seems to conjure feelings of uneasiness (what does this mean for me?), confusion (is this personal data, and do I need consent/re-consent to use it?), or exasperation (dealing with the flood of new privacy notices filling up your email inbox from other companies grappling with the same issues). The Regulation, which became law across all European countries in May 2018, intends to harmonise data protection practices across Europe. However, considerable ambiguity remains. This ambiguity – which arose in consideration of all six activities considered in our report – is principally around the appropriate legal basis for data processing in the absence of consent. Under the GDPR, pharmaceutical companies should be considered to have “legitimate interests” in processing data (Article 6), which due to its sensitive nature must and does undergo rigorous safeguarding activities, and must meet one of the additional legal bases for processing health data outlined in Article 9: (h) provision of health or social care, (i) public interest in the area of public health, or (j) scientific research. In our report we speculate which legal bases may be most appropriately applied to the six pharmaceutical activities studied, but clear guidance and consensus is required.

The legal barriers that arise in the utilisation of data by pharmaceutical companies vary across a product’s lifecycle. However, the main issues can be described under eight main themes.

  1. Data subject rights are not absolute and may be more limited within the context of health research due to the scientific or public interest merits of the data use, along with the high level of safeguards in place to protect data.
  2. Data ceases to be personal once anonymisation has been achieved, in which case it does not fall under data protection legislation. Where anonymisation is not possible, processors must have a legal basis for processing data.
  3. One such basis is (informed) consent. However, a key challenge is in constructing consent that is broad enough to permit later research, but specific enough to meet legal standards, particularly within the heightened requirements of the GDPR. We argue that these requirements are not usually compatible with medical research, and whilst consent is critical for other reasons, it should not usually be the legal basis for data processing.
  4. However, as outlined already, uncertainty around the appropriate legal basis for processing data under the GDPR is currently a major issue for industry.
  5. There is a need for a shared and consistent understanding of the compatibility of primary and secondary (re-)use of data.
  6. This addresses the heterogeneity both within and between countries that arises from divergent interpretations.
  7. There is a need for clear guidance or minimum standards for industry in the emerging area of digital health.
  8. Promoting confidence and engendering trust is fundamental and is achieved through being transparent and sharing good practice. The public must be convinced of the benefits of data processing for pharmaceutical research, and of the high safeguarding standards employed in handling their sensitive information. 

The GDPR was not designed to hamper important scientific research, and we propose that it does not create new legal barriers. In assessing the legal barriers to the better use of data, many of the issues we identified were uncertainties rather than barriers per se. Therefore, there is a strong case for industry to deal proactively with the uncertainties, sharing good practice and engendering trust by co-creating a code of conduct, outlining principles of responsible use.

We all have a stake in how our health data are collected and used to drive innovation and improvements in health care delivery. A shared understanding of the value to society of pharmaceutical research is therefore necessary and underpins our legal frameworks.

Citation

Cole, A. and Towse, A., 2018. Legal Barriers to Better the Better Use of Health Data to Deliver Pharmaceutical Innovation. OHE Consulting Report, London: Office of Health Economics.

Related research

Cole, A., Garrison, L., Mestre-Ferrandiz, J. & Towse, A., 2015. Data Governance Arrangements for Real-World Evidence. OHE Consulting Report, London: Office of Health Economics. RePEc.

  • Drug Development/R&D
  • Economics of Innovation
  • Consulting Reports

Related News

Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • August 2020

Are Discount Rates Used in UK Vaccine Economic Evaluations Jeopardising Investment in Immunisation Programmes?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!